Standalone quarter ended September 30, 2026: revenue up 127%, profit after tax up 97% year on year
BLUEJET · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the standalone quarter ended September 30, 2026, revenue from operations rose 127.1 percent year on year to INR 375.74 crore from INR 16.55 crore, and profit after tax rose 96.6 percent to INR 10.25 crore from INR 5.21 crore. EBITDA margin slipped from 33.2 percent to 31.6 percent. Standalone half-year profit was INR 18.08 crore; net operating cash flow was negative INR 2.56 crore. An INR 800 crore placement added 15.81 million shares.
Strong growth supports sentiment, but weaker margins, negative operating cash flow and dilution from the INR 800 crore placement are risks.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.